Sector
Healthcare
Industry
Biotechnology
Employees
621
First IPO Date
June 12, 2013
| Name | Title | Pay | Year Born |
| Patrick Crawford Reid | President, Chief Executive Officer & Representative Director | 126.8M | 1975 |
| Yen Ting Chen | Head of Business Development & Alliance Management | 0 | N/A |
| Christian Cunningham | Chief Scientific Officer | 0 | N/A |
| Masato Murakami | Executive VP of Radiopharmaceuticals Business, Chief Medical Officer & Director | 0 | 1974 |
| Yuko Okimoto | IR & Public Relations Director | 0 | N/A |
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.